📰 ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth
TLDR IBRX stock fell about 18% on Monday after a busy round of company news. Q3 net product revenue hit $48.7 million, up 53%, and nine-month revenue rose 92% to $143.6 million. ANKTIVA plus BCG met its primary goal in Cohort A of the QUILT-2.005 trial. Q3 net loss to common stockholders grew to $184.6 [...] The post ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth appeared first on Blockonomi.
Source : Blockonomi
Time : 2026-11-09 14:40:42
Credit : ken carey
#news #stocks
Share your opinion in the comment section below
TLDR IBRX stock fell about 18% on Monday after a busy round of company news. Q3 net product revenue hit $48.7 million, up 53%, and nine-month revenue rose 92% to $143.6 million. ANKTIVA plus BCG met its primary goal in Cohort A of the QUILT-2.005 trial. Q3 net loss to common stockholders grew to $184.6 [...] The post ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth appeared first on Blockonomi.
Source : Blockonomi
Time : 2026-11-09 14:40:42
Credit : ken carey
#news #stocks
Share your opinion in the comment section below